Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Interventions

ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Epidermolysis Bullosa Dystrophica × 1 year × Clear all
NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Salzburger Landeskliniken

Phase 1/2 Completed
2 enrolled

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica

NCT05843994 2026-02-03

Artificial Intelligence Patient App for RDEB SCCs

Northwestern University

Active not recruiting
20 enrolled
Dermatologic

Congenital Abnormalities, Carcinoma, Squamous Cell, Epidermolysis Bullosa, Skin Abnormalities, Skin Diseases, Skin Diseases, Vesiculobullous, Skin Diseases, Genetic, Skin Neoplasms, Epidermolysis Bullosa Dystrophica, Genetic Diseases, Inborn

NCT06423573 2025-09-19

FOSteR

Amryt Pharma

Recruiting
580 enrolled

Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional

Data powered by HemOnc (CC BY 4.0) Colophon âš¡